Status:

TERMINATED

Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection

Lead Sponsor:

Gilead Sciences

Conditions:

Chronic Hepatitis B

Eligibility:

All Genders

18+ years

Brief Summary

This study will evaluate the long term effects of hepatitis B virus (HBV) treatment on the HBV serologic changes and HBV DNA levels through Week 144. This registry will enroll only individuals who wer...

Eligibility Criteria

Inclusion

  • Key
  • Must have participated in a Gilead-sponsored chronic hepatitis B (CHB) study no more than 120 days prior to Baseline (Day 1), except for participants from previous Gilead-sponsored study number GS-US-174-0149, who will have up to one year from their last visit in that protocol.
  • Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
  • Must be willing and able to comply with the visit schedule and study requirements
  • Must have documented HBV DNA \< 2,000 IU/mL at time of screening visit, which shall occur no later than 1 year post last study visit in GS-US-174-0149
  • Must have documented hepatitis B surface antigen (HBsAg) negative status anytime during participation in GS-US-174-0149 regardless of ongoing HBV treatment
  • Key

Exclusion

  • Patient participating or planning to participate in another clinical study with an investigational agent
  • History of clinically-significant illness or any other major medical disorder that may interfere with follow-up, assessments or compliance with the protocol
  • Believed by the Study Investigator to be inappropriate for study participation for any reason not otherwise listed
  • Received TDF monotherapy either as part of GS-US-174-0149 Arm C (TDF monotherapy arm) or for TDF retreatment, and have taken any HBV antiviral therapy since completion of GS-US-174-0149
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Key Trial Info

Start Date :

December 9 2014

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

August 14 2017

Estimated Enrollment :

241 Patients enrolled

Trial Details

Trial ID

NCT02258581

Start Date

December 9 2014

End Date

August 14 2017

Last Update

October 3 2017

Active Locations (37)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 10 (37 locations)

1

Kaiser Permanente

Sacramento, California, United States

2

Kaiser Permanente

San Diego, California, United States

3

Kaiser Permanente

San Francisco, California, United States

4

Silicon Valley Research Institute

San Jose, California, United States